跳轉至內容
Merck
全部照片(1)

Key Documents

05-636-AF488

Sigma-Aldrich

抗磷酸化组蛋白H2A.X (Ser139) ,克隆JBW301,Alexa Fluor 488 结合抗体

clone JBW301, from mouse, ALEXA FLUOR 488

同義詞:

Histone H2AX, H2a/x, Histone H2A.X

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

mouse

品質等級

共軛

ALEXA FLUOR 488

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

JBW301, monoclonal

物種活性

human

物種活性(以同源性預測)

vertebrates (based on 100% sequence homology)

技術

immunocytochemistry: suitable

同型

IgG1

NCBI登錄號

UniProt登錄號

運輸包裝

wet ice

目標翻譯後修改

phosphorylation (pSer139)

基因資訊

human ... H2AX(3014)

一般說明

组蛋白H2A.X是组蛋白H2A的变体,与基因组DNA相似。但是,组蛋白在结构上与H2A家族的其他成员不同,因为它具有一个C末端尾巴,该尾巴包含Ser139残基,该残基响应于双链DNA的断裂而被磷酸化。H2A.X的磷酸化是由ATM/ATR蛋白介导的快速过程。

應用

该抗磷酸化组蛋白H2A.X(Ser139)抗体(克隆JBW301,Alexa Fluor 488偶联物)经验证可用于ICC检测磷酸化组蛋白H2A.X(Ser139)。

品質

通过免疫细胞化学在未处理(阴性对照)和星形孢菌素处理的HeLa细胞中进行评估。

免疫细胞化学分析:来自代表性批次的1:100稀释液在星形孢菌素处理的HeLa细胞中检测到磷酸组蛋白H2A.X(Ser139),而在未处理的HeLa细胞中未检测到。

標靶描述

计算分子量为17 kDa

其他說明

浓度:请参考批次特异性浓缩物的分析证书。

法律資訊

ALEXA FLUOR is a trademark of Life Technologies

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Lara H El Touny et al.
Oncotarget, 12(21), 2114-2130 (2021-10-23)
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMTlow/-ve/MMRproficient patients benefit from TMZ treatment, indicating a need for
Lidia F Hernandez et al.
Cell death discovery, 7(1), 134-134 (2021-06-06)
Ovarian cancer is the most lethal gynecological cancer in the US. Standard treatment consists of surgery followed by chemotherapies relying on apoptotic tumor cell death. Most women with advanced stage disease will relapse, suggesting that this disease is characterized by
Jolien Van den Bossche et al.
Cancers, 11(12) (2019-12-05)
Polo-like kinase 1 (Plk1), a master regulator of mitotic cell division, is highly expressed in non-small cell lung cancer (NSCLC) making it an interesting drug target. We examined the in vitro therapeutic effects of volasertib, a Plk1 inhibitor, in combination
Lihua H Wang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1073-1084 (2010-01-28)
Circulating tumor cells (CTC) in peripheral blood of patients potentially represent a fraction of solid tumor cells available for more frequent pharmacodynamic assessment of drug action than is possible using tumor biopsy. However, currently available CTC assays are limited to
Manman Xu et al.
Cancers, 14(24) (2022-12-24)
DNA double-strand breaks (DSBs) caused by platinum drugs are dangerous lesions that kill cancer cells in chemotherapy. Repair of DSB by homologous recombination (HR) and nonhomologous end joining (NHEJ) is frequently associated with platinum resistance in ovarian cancer. While the

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務